Herman William H, Kuo Shihchen
Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI.
Diabetes Care. 2025 Sep 1;48(9):1465-1471. doi: 10.2337/dci24-0103.
The American Diabetes Association (ADA) publishes the "Standards of Care in Diabetes" (SOC) annually to offer clinicians, patients, and payers evidence-based guidelines for diabetes management. The 2025 SOC recommends that clinicians consider screening asymptomatic adults with diabetes for heart failure using natriuretic peptide levels, and that they screen asymptomatic adults with diabetes ≥65 years of age with any microvascular disease, foot complications, or end-organ damage from diabetes for peripheral artery disease (PAD) using ankle-brachial index (ABI) testing. This perspective evaluates those recommendations using established screening principles and the published literature. The recommendation to screen for heart failure using natriuretic peptide lacks robust evidence in several key areas. N-terminal pro-B-type natriuretic peptide, or NT-proBNP, itself performs poorly as a screening test in asymptomatic adults. Furthermore, there is ambiguity in treatment recommendations and insufficient evidence showing improved outcomes with sodium-glucose cotransporter 2 inhibitor treatment in adults with diabetes and stage B heart failure. Finally, the costs involved are high and may not be economically justifiable. Similarly, the recommendation to screen for PAD in asymptomatic adults with diabetes is not backed by rigorous scientific evidence. The evidence cited combines ABI screening with other effective screening tests and has limited generalizability. There is no guidance on how to interpret the results of ABI testing or how the information gained should be used to direct treatment. While the intent to improve health care through screening is commendable, these recommendations are inadequately supported by the principles of screening and the published literature. It is imperative that the ADA uses the greatest scientific rigor to prepare its SOC.
美国糖尿病协会(ADA)每年发布《糖尿病诊疗标准》(SOC),为临床医生、患者和支付方提供基于证据的糖尿病管理指南。2025年版SOC建议临床医生考虑使用利钠肽水平对无症状糖尿病成年人进行心力衰竭筛查,并使用踝臂指数(ABI)检测,对年龄≥65岁、患有任何微血管疾病、足部并发症或糖尿病所致终末器官损害的无症状糖尿病成年人进行外周动脉疾病(PAD)筛查。本文从既定的筛查原则和已发表的文献角度对这些建议进行评估。使用利钠肽筛查心力衰竭的建议在几个关键领域缺乏有力证据。N末端B型利钠肽原(NT-proBNP)本身作为无症状成年人的筛查试验效果不佳。此外,治疗建议存在模糊性,且缺乏足够证据表明钠-葡萄糖协同转运蛋白2抑制剂治疗可改善糖尿病合并B期心力衰竭成年人的预后。最后,相关成本高昂,在经济上可能不合理。同样,对无症状糖尿病成年人进行PAD筛查的建议也缺乏严格的科学证据支持。所引用的证据将ABI筛查与其他有效筛查试验结合在一起,普遍适用性有限。对于如何解读ABI检测结果或如何利用所获得的信息指导治疗,没有相关指导。虽然通过筛查改善医疗保健的意图值得称赞,但这些建议在筛查原则和已发表文献方面缺乏充分支持。ADA必须以最严谨的科学态度制定其SOC。